Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-030879
Filing Date
2019-08-08
Accepted
2019-08-08 16:53:57
Documents
56
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q achv-10q_20190630.htm 10-Q 1911921
2 EX-31.1 achv-ex311_9.htm EX-31.1 9049
3 EX-31.2 achv-ex312_8.htm EX-31.2 9085
4 EX-32.1 achv-ex321_7.htm EX-32.1 4839
5 EX-32.2 achv-ex322_6.htm EX-32.2 4864
  Complete submission text file 0001564590-19-030879.txt   6475848

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT achv-20190630.xml EX-101.INS 1280077
7 XBRL TAXONOMY EXTENSION SCHEMA achv-20190630.xsd EX-101.SCH 50257
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE achv-20190630_cal.xml EX-101.CAL 45335
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20190630_def.xml EX-101.DEF 182014
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20190630_lab.xml EX-101.LAB 401039
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20190630_pre.xml EX-101.PRE 309889
Mailing Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101
Business Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 191010319
SIC: 2835 In Vitro & In Vivo Diagnostic Substances